SC
CMPX icon

SummitTX Capital’s Compass Therapeutics CMPX Stock Holding History

SummitTX Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3K Buy
+12,000
New +$35.4K ﹤0.01% 755
2026
Q1 		– Sell
-81,449
Closed -$437K – 805
2025
Q4 		$437K Buy
+81,449
New +$376K 0.01% 547

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SummitTX Capital's CMPX Position: Q2 2026 in Review

SummitTX Capital opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 12,000 shares worth $26.3K. The stake represents ﹤0.01% of the portfolio and ranks #755 among its holdings. This is a return to the name: SummitTX Capital previously reported a position in CMPX as recently as Q4 2025.

SummitTX Capital first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. The position peaked at $437K in Q4 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • SummitTX Capital held 12,000 shares of Compass Therapeutics worth $26.3K as of Q2 2026.
  • Compass Therapeutics was a new SummitTX Capital position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of SummitTX Capital's portfolio in Q2 2026, its #755 holding.
  • SummitTX Capital first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • SummitTX Capital's Compass Therapeutics position peaked at $437K in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.